Following a year of exceptional progress in IBD drug development, fierce competition in clinical trials for Chron’s Disease and Ulcerative Colitis remains high, and it’s time for biopharma to push the boundaries of efficacy and distinguish their therapies amongst the market.
See the full program here: https://ter.li/tjjok6
With transformative advancements in disease understanding, AI-powered biomarker development, patient stratification, and advanced monitoring techniques paving the way for a new era of precision IBD therapies, join 80+ IBD specialists to:
- Refine models and proof-of-concept studies to reduce clinical trial failure rates and improve translational outcomes
- Innovate treatment pathways to optimize safety and efficacy
- Minimize adverse events while enhancing therapeutic synergies
- Leverage emerging therapeutic modalities to refine patient selection and optimize therapeutic outcomes
When & Where: May 13-15, 2025 | Boston, MA
Who: 80+ Precision Medicine, Diagnostics, Translational, Clinical, Computational Biology, Gastrointestinal and Inflammation experts
Agenda: https://ter.li/tjjok6